Clinical trials: Thromboembolic Disease
Venous Thromboembolism, Pharmacokinetics
Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus
This study aims to evaluate the pharmacokinetics (PK) of apixaban when co-administered with cyclosporine and tacrolimus in healthy volunteers.
- Conditions
- Venous Thromboembolism, Pharmacokinetics, Healthy
- Trial name
- ACT (NCT03083782)
- Testing
- Apixaban alone, Cyclosporine, Tacrolimus
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Pulmonary Thromboembolisms, Pulmonary Embolism
Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events
Deep vein thrombosis (DVT) occurs when a blood clot forms in a deep vein, typically in the lower extremities. Pulmonary embolism (PE) occurs when a DVT clot (or fragment) breaks free and travels through the heart to the pulmonary…
- Trial name
- NCT03183063
- Testing
- 4DCT and SPECT/CT, 4DCT with BiPAP and SPECT/CT, 4DCT with CTA in suspected PE
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Thomas Guerrero
Pulmonary Hypertension, Pulmonary Thromboembolisms
Longitudinal Study to Identify Predictive Factors of Post-thrombotic Pulmonary Hypertension
The current data on the incidence of pulmonary hypertension (PH) are very variable, depending on the different studies designs. There are no data on the prognostic of PH in patients with asymptomatic pulmonary thromboembolisms…
- Trial name
- NCT03134898
- Where
- 23 sites in Spain
- Volunteers
- 1,025 people
- Sponsor
- Sociedad Española de Neumología y Cirugía Torácica
Venous Thromboembolism, Cancer
Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients
Cancer patients have an increased risk of developing blood clots in the veins compared to non-cancer patients. Cancer patients who develop blood clots can lead to reduced life expectancy, delayed cancer treatment, and decreased…
- Trial name
- AVERT (NCT02048865)
- Testing
- Apixaban
- Where
- 14 sites in Canada
- Volunteers
- 575 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism
Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities
The study objective is to evaluate the efficacy and safety of oral YM150 for prevention of venous thromboembolism in subjects undergoing hip fracture surgery or surgery in the lower extremities.
- Trial name
- NCT00937911
- Testing
- YM150
- Where
- 8 sites in Japan
- Volunteers
- 101 people
- Sponsor
- Astellas Pharma Inc
Pulmonary Embolism
Crux Biomedical Vena Cava Filter Study - United States
The purpose of this study is to determine if the Crux Vena Cava Filter System is safe and effective in preventing pulmonary embolism.
- Trial name
- RETRIEVE 2 (NCT01120509)
- Testing
- Inferior Vena Cava Filter
- Where
- 17 sites in United States
- Volunteers
- 88 people
- Sponsor
- Crux Biomedical
Pulmonary Embolism
Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism
This study will test the hypothesis that patients with acute PE and dyspnea can safely inhale NO. The secondary hypothesis is that patients who are blinded to the inhaled NO concentration will sustain subjective improvement in…
- Trial name
- NCT00848731
- Testing
- nitric oxide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Wake Forest University Health Sciences
Recurrent Venous Thrombosis
Risk of Recurrent Venous Thromboembolism After Provoked Venous Thromboembolism
Venous thromboembolism (VTE) is a common disease with an incidence of 1-2/1000 persons per year. VTE is a chronic disease with a considerable risk of recurrence. Patients with unprovoked VTE, i.e.
- Trial name
- AURECpro (NCT04124159)
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Venous Thromboembolism
Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
The purpose of this study is to assess different doses of a new drug (BAY 59-7939), taken as a tablet, are safe and can help prevent blood clots forming after a hip replacement operation.
- Trial name
- ODIXaHIP-OD (NCT00396786)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 62 sites in Austria, Belgium and 11 more
- Volunteers
- 877 people
- Sponsor
- Bayer
Thromboembolic Disease
Impact of Remote Care in Patients Diagnosed With Thromboembolic Disease of Low Risk
The goal of this clinical trial is to learn about the feasibility and impact of remote care in patients diagnosed with thromboembolic disease of low risk.
- Trial name
- TEVEDOM (NCT05684770)
- Testing
- 4G tablet
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Eure-Seine
Sickle Cell Disease, Venous Thrombosis
Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
Background: Venous thromboembolism (VTE) includes the abnormal clotting of blood in a deep vein of the upper or lower limbs (deep vein thrombosis) that may travel to and block a blood vessel in the lung (pulmonary embolism).
- Conditions
- Sickle Cell Disease, Venous Thrombosis, Sickle Cell Trait, Hypercoagulable State
- Trial name
- NCT04349189
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Prevention, Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and can help prevent blood clots forming after a hip replacement operation.
- Trial name
- RECORD 2 (NCT00332020)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 126 sites in United States, Australia and 21 more
- Volunteers
- 2,457 people
- Sponsor
- Bayer
Atrial Fibrillation (AF)
Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation
The DESTINATION Study investigates whether anticoagulation therapy is necessary after successful catheter ablation (CA) for atrial fibrillation (AF).
- Trial name
- DESTINATION (NCT06615596)
- Testing
- discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
- Where
- 12 sites in United States, China
- Volunteers
- 3,160 people
- Sponsor
- China National Center for Cardiovascular Diseases
Pulmonary Hypertension
Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
The present trial investigates the long-term safety, tolerability and efficacy of bosentan in patients with inoperable CTEPH.
- Trial name
- BENEFIT OL (NCT00319111)
- Testing
- bosentan
- Volunteers
- 151 people
- Sponsor
- Actelion
Venous Thromboembolism (VTE), NSCLC (Advanced Non-small Cell Lung Cancer)
Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer
Multicenter, prospective observational study (15 Oncologic Centers, in Italy). The purpose of the study is to assess the thromboembolic potential in patients with oncogene-addicted and wild-type NSCLC.
- Trial name
- NCT07288632
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- University Of Perugia
Venous Thromboembolism
Thromboembolic and Hemorrhagic Complications of Anticoagulant Treatment in Patients With CAT
The study is classified as an observational pharmacological study, spontaneous, monocentric, and both retrospective and prospective for adult patients with a diagnosis of venous thromboembolism in the context of neoplasia…
- Trial name
- NCT06714734
- Where
- 2 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Venous Thromboembolism
Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
The purpose of this study is to evaluate the efficacy and safety of new oral anticoagulants and vitamin K antagonists for the anticoagulation for the implantation of vena cava filters in patients with deep venous thrombosis.
- Trial name
- EPICT (NCT04066764)
- Testing
- Rivaroxaban, Warfarin, Nadroparin
- Where
- 7 sites in China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Chronic Thromboembolic Pulmonary Disease
Symptom-driven Referral for Evaluation of Chronic Thromboembolic Disease or Pulmonary Hypertension in Patients With Previous Acute Pulmonary Embolism
Aim: To investigate if a symptom driven referral for chronic thrombosis in the lungs after acute pulmonary embolism is better than the current approach.
- Trial name
- NCT03729492
- Testing
- CTEPH/CTED work-up
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Venous Thromboembolism, Arterial Thromboembolism
A Universal Electronic Health Record-based IMPROVE DD VTE Risk Assessment Model for the Prevention of Thromboembolism in Hospitalized Medically Ill Patients
This study will be a multicenter clustered randomized trial of patients in hospitals in which a universal "SMART on FHIR" platform-based EHR-embedded IMPROVE DD VTE clinical prediction rules (CPRs) with electronic order entry has…
- Trial name
- NCT04768036
- Testing
- IMPROVE DD VTE Tool
- Where
- 5 sites in United States
- Volunteers
- 10,699 people
- Sponsor
- Northwell Health
Cerebral Stroke, Cerebral Venous Thrombosis
Intracranial Hypertension and Optic Nerve Sheath Diameter
Intracranial hypertension (ICH) is a mortality risk factor in severe traumatic brain injury (TBI), in purulent meningitis, in hepatic encephalopathy and in Reye's syndrome.
- Trial name
- DENO (NCT01796015)
- Testing
- ONSD ultrasound
- Where
- 2 sites in France
- Volunteers
- 230 people
- Sponsor
- Hospices Civils de Lyon